Chemotherapeutic purine analogs alter the level of interferon-beta mRNA induced by poly I-poly C in cultured osteosarcoma cells.
The purine nucleoside analogs fludarabine, 2-chlorodeoxyadenosine, and 2'-deoxycoformycin exhibit impressive activity in lymphoproliferative malignancies of adults and children. Their mechanism of action is not clear. Studies have suggested that their use is associated with significant myelosuppression, immunosuppression, and in some circumstances, increased infection with viral and opportunistic pathogens. Because interferons (IFNs) are known to have immunomodulatory activity as well as potent antiproliferative and antiviral activity, we examined whether the chemotherapeutic purine nucleoside analogs alter interferon-beta (IFN-B) gene expression in MG63 in human osteosarcoma cells. Northern blot analysis showed a dose-dependent inhibition of IFN-B mRNA accumulation in response to a known inducer (Poly I-Poly C) all three purine analogs. Hybridization analysis also revealed that inhibition of IFN-beta mRNA accumulation by the purine analogs is not a result of decreased mRNA stability. Further analysis of gene expression by PCR differential display indicated that the effect of the purine analogs was restricted to only a limited number of inducible genes. The data suggest that these molecules alter the signaling process involved in regulating the expression of specific genes, including IFN-beta. These findings predict that the use of purine nucleoside analogs may reduce IFN production in vivo and thereby abrogate host defenses against infectious pathogens.
Slomiany
D J
DJ
Department of Hematology/Oncology, Children's National Medical Center, Washington, DC., USA.
Woldehawariat
G
G
Petryshyn
R A
RA
D000970:Antineoplastic Agents / Q000009:adverse effects*; D017338:Cladribine / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D016899:Interferon-beta / Q000235:genetics*; D014411:Neoplastic Stem Cells; D015649:Pentostatin / Q000009:adverse effects*; D011070:Poly I-C / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects; D012333:RNA, Messenger / Q000032:analysis*; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*; D019892:eIF-2 Kinase
D000970:Antineoplastic Agents; D012333:RNA, Messenger; D015649:Pentostatin; D017338:Cladribine; D016899:Interferon-beta; D017346:Protein Serine-Threonine Kinases; D019892:eIF-2 Kinase; D014740:Vidarabine; D011070:Poly I-C; C024352:fludarabine